- Conditions
- Rheumatoid Arthritis
- Interventions
- Fostamatinib, Rosuvastatin, Simvastatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1081–1104
of 1,904
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Bevespi, Bretzri
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Stable Coronary Artery Disease (CAD), Myocardial Infarction
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 9,284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 34
- States / cities
- Huntsville, Alabama • Los Angeles, California • Santa Ana, California + 31 more
- Conditions
- Renal Impairment
- Interventions
- AZD9977
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 6
- States / cities
- Northridge, California • DeLand, Florida • Hialeah, Florida + 3 more
- Conditions
- Type 2 Diabetes
- Interventions
- Saxagliptin, Placebo, Metformin (blinded), Metformin (open-label)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 3
- States / cities
- San Diego, California • Baton Rouge, Louisiana • San Antonio, Texas
- Conditions
- Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
- Interventions
- AZD9291
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 603 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 3 more
- Conditions
- Healthy Subjects
- Interventions
- AZD1979, Placebo to match
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy, Memory Impairment
- Interventions
- AZD8529, Placebo to match AZD8529
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma, Weight Management
- Interventions
- No treatment given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2039
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Durvalumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- The Bronx, New York • Houston, Texas • Charlottesville, Virginia
- Conditions
- Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
- Interventions
- Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment, Survey Administration, Testosterone Enanthate, Testosterone Cypionate
- Other · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hypertension, Aldosterone Disorder, Cardiovascular Disease (CVD)
- Interventions
- observational study
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Hidradenitis Suppurativa
- Interventions
- MEDI8968, Saline
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Bakersfield, California • Fremont, California + 24 more
- Conditions
- Ovarian Cancer
- Interventions
- Olaparib, Ceralasertib, Placebo to match olaparib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 22
- States / cities
- Anchorage, Alaska • La Jolla, California • Long Beach, California + 18 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Volrustomig, Carboplatin, Pemetrexed, Ramucirumab, Paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Chapel Hill, North Carolina
- Conditions
- Dyslipidaemia
- Interventions
- AZD0780, Itraconazole, Carbamazepine, Midazolam, Ethinyl estradiol/levonorgestrel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab, Tremelimumab, Thoracic Radiation, lobectomy, Standard of care adjuvant chemotherapy
- Drug · Radiation · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Advanced Chronic Liver Disease, Healthy Participants
- Interventions
- AZD2389, Quinidine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Osimertinib + Savolitinib, Savolitinib + Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Duarte, California • Sacramento, California
- Conditions
- Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
- Interventions
- MEDI4736, Tremelimumab, MEDI4736 + Tremelimumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 96 Years
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Yuma, Arizona • Little Rock, Arkansas + 38 more
- Conditions
- Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Interventions
- AZD8853, Zirconium-89 crefmirlimab berdoxam
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • St Louis, Missouri • Providence, Rhode Island + 1 more
- Conditions
- Solid Tumours
- Interventions
- Savolitinib, Famotidine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
- Interventions
- AZD 1775
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 13
- States / cities
- Fayetteville, Arkansas • San Francisco, California • West Hollywood, California + 10 more